| Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. | |
| | |
MedLine Citation:
|
PMID: 20926977 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
PURPOSE: Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) has added positron emission tomography (PET) as an optional complement for the detection of new lesions. In this study, we evaluate the utility of fluorodeoxyglucose (FDG)-PET in the identification of new lesions and progressive disease not recognized on computed tomography (CT) in patients with nonsmall cell lung cancer (NSCLC) undergoing therapy. MATERIALS AND METHODS: Seventy patients (30 female, 40 male; mean age 67±14 years, range, 39-94 years) with NSCLC underwent FDG-PET before and after chemotherapy and/or radiotherapy, whereas 69 patients underwent CT imaging. Overall (OS) and progression-free survivals (PFS) were calculated for RECIST 1.1 with CT alone, RECIST 1.1 with PET for the identification of new lesions, visual PET, and semiquantitative PET using a change in standardized uptake value ranging from -15 to -50%. RESULTS: PET identified new lesions in 26 patients, resulting in 10 patients (14.5%) being upgraded to progressive disease. The combination of CT and PET for the detection of new lesions improved the prediction of survival (OS: P=0.0491 for all stages and P=0.0033 for stage IV; PFS: P=0.0045 for stage IV) compared with CT imaging alone (OS: P=0.1362 for all stages and P=0.1625 for stage IV; PFS: P=0.0632 for stage IV). Furthermore, a change in standardized uptake value of -35% was the most discriminative for the prediction of survival for the semiquantitative PET approach (OS: P=0.0393 for all stages, P=0.0051 for stage IV; PFS: P=0.0092 for stage IV) and more discriminative than the visual PET approach (OS: P=0.2699 for all stages, P=0.0105 for stage IV; PFS: P=0.014 for stage IV). CONCLUSION: FDG-PET is helpful in identifying new lesions in NSCLC patients, resulting in the improved assessment of therapy response with CT imaging combined with FDG-PET compared with CT imaging alone. Although RECIST 1.1 includes FDG-PET only as an optional adjunct, we recommend the implementation of PET imaging in the assessment of therapy response. |
| | |
Authors:
|
Sebastian Obrzut; Julie Bykowski; Karam Badran; Mohammad Reza Hayeri; Carl K Hoh |
Related Documents
:
|
7589597 - Contribution of pet in the diagnosis of recurrent colorectal cancer: comparison with co... 19190917 - Whole-body mri at 1.5 t and 3 t compared with fdg-pet-ct for the detection of tumour re... 12752087 - Accuracy of whole-body 18f-fdp-pet for restaging malignant lymphoma. 19917927 - Neck response to chemoradiotherapy: complete radiographic response correlates with path... 11105707 - Mr arteriography using an implantable port system: a new method in assessing perfusion ... 7589597 - Contribution of pet in the diagnosis of recurrent colorectal cancer: comparison with co... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 31 ISSN: 1473-5628 ISO Abbreviation: Nucl Med Commun Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 1008-15 Citation Subset: IM |
Affiliation:
|
Department of Radiology, University of California San Diego, La Jolla, California, USA. sobrzut@ucsd.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Monitoring of 2-deoxy-2-[18F]fluoro-D-glucose uptake in tumor-bearing mice using high-sensitivity pr...
Next Document: Distribution pattern of 68Ga-DOTATATE in disease-free patients.